Protalix BioTherapeutics (PLX) Current Deferred Revenue (2010 - 2025)

Protalix BioTherapeutics' Current Deferred Revenue history runs 16 years deep, the most recent figure standing at $2.0 million for Q1 2025.

• In Q1 2025, Current Deferred Revenue fell 81.88% year-over-year to $2.0 million; the TTM figure through Mar 2025 stood at $2.0 million (down 81.88% YoY), while the FY2022 annual figure was $13.2 million, up 54.13% from the prior year.
• Current Deferred Revenue for Q1 2025 stood at $2.0 million, down from $12.7 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $18.1 million in Q2 2021, with the low at $2.0 million in Q1 2025.
• The 5-year median for Current Deferred Revenue is $11.8 million (2022), against an average of $11.0 million.
• The sharpest annual moves came in 2021 and 2022: Current Deferred Revenue slumped 86.54% in 2021, then soared 360.98% in 2022.
• Protalix BioTherapeutics' Current Deferred Revenue stood at $8.5 million in 2021, then surged by 54.13% to $13.2 million in 2022, then declined by 10.53% to $11.8 million in 2023, then climbed by 7.68% to $12.7 million in 2024, then slumped by 84.25% to $2.0 million in 2025.
• Business Quant data shows PLX's Current Deferred Revenue at $2.0 million in Q1 2025, $12.7 million in Q2 2024, and $11.0 million in Q1 2024.